Novo Nordisk nach Split WKN: A3EU6F ISIN: DK0062498333 Kürzel: NOV Forum: Aktien User: Coronaprofiteur

$50 EOY wenn es gut läuft...

Ich hätte nichts dagegen 👍

Kann nur hoffen das es fliegende Shortseller sind

Heute 40€

Was ist da schon wieder los?

Road to 30

Damit genau solche shorter wie du reingelegt werden🙂

Geht schon wieder Richtung Jahrestief!

https://de.marketscreener.com/boerse-nachrichten/novo-nordisk-sieht-potenzial-jenseits-von-adipositas-und-diabetes-ce7f5dd2df88f522

https://de.marketscreener.com/boerse-nachrichten/novo-nordisk-vermeldet-positive-phase-3-ergebnisse-fuer-cagrisema-bei-typ-2-diabetes-ce7f5dd2df8af72d

Heute wird ordentlich Kasse gemacht, geht ja jetzt schon wieder runter

Na dann mal hoffen dass Nahost nicht alles zu nichte macht

Novo Nordisk CEO blickt über Gewichtsverlust hinaus auf Langlebigkeit und Ästhetik https://www.reddit.com/r/NovoNordisk_Stock/s/WHyHH0kGuQ Top genau das meinte ich mit peptide außerhalb der abnehmbranche 👌

Novo Nordisk’s CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026 https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916567

Interessant wäre warum novo das studiendesign so strikt ausgewählt hat. Phase 3 wird ganz anders Abbruchraten haben als diese Phase 2 Studie. Das ist wirklich wichtig, dass man die Ergebnisse richtig einordnet. Verschiedene studie miteinander zu vergleichen ist wirklich sehr schwer und meistens von geringer aussagekraft. Novo zeigt ja auch in den real World Daten das Semaglutid bei t2d besser ist als Tirzepatide.

Mayor NEWS. Zenagamtide study discontinuation in new T2D trial, is extremely INFLATED. Since $NVO presented P2 data with Zenagamtide/Amycretin in T2D, at lot of people including me have looked at the data and thought somethings wrong. 5mg up to 40mg had 16-34% discontinuation on side effects 😳 that would be a commercial disaster if “true” But looking at side effects for nausea, vomiting and Diarrhea, they did not reflect sky high incidents, what most would envision to hit 16-34% discontinuation. Also from comparing with other data by Tirzepatide and Retatrutide. Something did not add up. But @flippyfloppy52 has found the reason. And that’s in how the protocol is designed. It’s much much more strict on how to determine if a trial participant should be counted as discontinuation due to side effects. In Zenagamtide protocol you would be forced to leave the trial, if you are not able to take the next dose as scheduled. “This trial used a fixed-dose-escalation trial design; if the planned treatment dose was not tolerated, treatment was permanently discontinued.” Meaning if you just tittered up to 20mg and you get overwhelmed with nausea and maybe vomit 1 time. You ask I you can delay taking the next dose. Or maybe even go back to 10mg for a few more weeks before up-titration to 20mg again. In this trial you got booted immediately if you could not take the next dose as scheduled. Then you would be registered as discontinuation due to side effects. @flippyfloppy52 looked up at Tirzepatide study. And I just looked up Retatrutide 36 week P2 in T2D. In those trials there’s much much more flexibility. Picture from Retatrutide P2 in T2D. Here you can completely miss more than 2 dosing and when you are ready to start again you can start at a lower dose. This difference in how to determine what an investigator initiated discontinuation due to side effects are. This completely change the storyline of how unattractive Zenagamtide is when up to 34% had to quit the trial. Why NVO not have made this huuuuge difference more visible by stating it in the poster. I don’t know. But what I do know is investors at multiple different national and global investors sites has been discussing how bad this looked for Zenagamtide and $NVO I hope $NVO explicitly talks in to this, when they later today will have their ADA investor presentation. These very unfavourable discontinuation numbers are reflecting THIS specific trial design. All ongoing P3 trials have flexible dosing giving participants the possibility to start at lower doses etc. @maziardoustdar @mnovod79 $LLY $VKTX